Australia markets close in 3 hours 25 minutes

Talis Biomedical Corporation (TLIS)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
8.99+0.14 (+1.52%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 15.71M
Enterprise value -41.36M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)38.03
Price/book (mrq)0.23
Enterprise value/revenue -100.38
Enterprise value/EBITDA 0.63

Trading information

Stock price history

Beta (5Y monthly) 1.74
52-week change 317.58%
S&P500 52-week change 323.57%
52-week high 39.32
52-week low 34.35
50-day moving average 38.64
200-day moving average 37.33

Share statistics

Avg vol (3-month) 39.2k
Avg vol (10-day) 38.89k
Shares outstanding 51.82M
Implied shares outstanding 61.84M
Float 81.01M
% held by insiders 18.31%
% held by institutions 143.93%
Shares short (15 Apr 2024) 412.26k
Short ratio (15 Apr 2024) 41.54
Short % of float (15 Apr 2024) 41.05%
Short % of shares outstanding (15 Apr 2024) 40.67%
Shares short (prior month 15 Mar 2024) 413.93k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 306 July 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-7,413.33%

Management effectiveness

Return on assets (ttm)-30.33%
Return on equity (ttm)-63.32%

Income statement

Revenue (ttm)2.13M
Revenue per share (ttm)1.17
Quarterly revenue growth (yoy)-24.10%
Gross profit (ttm)N/A
EBITDA -63.28M
Net income avi to common (ttm)-62.01M
Diluted EPS (ttm)-34.12
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)76.73M
Total cash per share (mrq)42.11
Total debt (mrq)19.67M
Total debt/equity (mrq)28.46%
Current ratio (mrq)8.86
Book value per share (mrq)37.93

Cash flow statement

Operating cash flow (ttm)-53.24M
Levered free cash flow (ttm)-36.33M